title: Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study.
abstract: OBJECTIVE
  We examined the completion rate, safety, and adverse events in patients with T2N0 glottic carcinoma who received chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium).
  
  
  METHODS
  In T2N0 glottic carcinoma patients, we retrospectively compared the local control rate and outpatient therapy completion rate between 20 patients who received radiotherapy plus S-1 (S-1 group) and 20 who received radiotherapy alone (RT group).
  
  
  RESULTS
  Local recurrence was not detected in any of the 20 subjects from the S-1 group, whereas local recurrence was found in 4 of the 20 subjects (20%) from the RT group (p<0.05). Outpatient treatment was completed by 15 of the 20 subjects from the S-1 group and 17 of the 20 subjects from the RT group (p=0.43).
  
  
  CONCLUSIONS
  We investigated chemoradiotherapy with S-1 in patients who had T2N0 glottic carcinoma and found a higher local control rate when compared with radiotherapy alone as well as comparable safety for outpatient delivery.
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan. Electronic address: oto061@poh.osaka-med.ac.jp.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Higashino
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Kawata
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan.
authors.forename: Koutetsu
authors.initials: K
authors.lastname: Lee
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan.
authors.forename: Shuji
authors.initials: S
authors.lastname: Nishikawa
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan.
authors.forename: Shimpei
authors.initials: S
authors.lastname: Ichihara
authors.affiliation: Department of Radiology, Osaka Medical College, Takatsuki, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Uesugi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000628:therapy*; D059248:Chemoradiotherapy; D004338:Drug Combinations; D005931:Glottis; D006801:Humans; D007822:Laryngeal Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D052016:Mucositis / Q000209:etiology; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D028761:Withholding Treatment
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid
keywords: Chemoradiation; Laryngeal preservation; Outpatient completion rate; S-1; T2N0 glottic carcinoma